08.03.2014 Views

ELECTRONIC POSTER - ismrm

ELECTRONIC POSTER - ismrm

ELECTRONIC POSTER - ismrm

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

appropriately describes the uptake behavior at tumor margins. We propose a model selection criterion that accounts for the adequacy<br />

both of model fit and of model complexity. DCE-MRI scans from breast cancer data are evaluated with the proposed model selection<br />

criterion per voxel: at tumor margins the proposed two tissue compartment model outperforms the standard one compartment model.<br />

14:00 4813. Cross-Visit Tumour Sub-Segmentation May Reveal Localised Response to Anti-<br />

Angiogenic Treatment in DCE-MRI Data<br />

Giovanni Alessandro Buonaccorsi 1 , Caleb Roberts 1 , James O’ Connor 1 , Chris Rose 1 , Sue<br />

Cheung 1 , Yvonne Watson 1 , Karen Davies 1 , Lynn Hope 2 , Alan Jackson 1 , Gordon Jayson 2 ,<br />

Geoff Parker 3<br />

1 Imaging Science and Biomedical Engineering, University of Manchester, Manchester , United Kingdom;<br />

2 Cancer Research UK Dept of Medical Oncology, Christie Hospital, Manchester, United Kingdom; 3 Imaging<br />

Science and Biomedical Engineering, University of Manchester, Manchester, United Kingdom<br />

Using DCE-MRI data from four patients enrolled in a trial of a VEGF inhibitor, we performed cross-visit tumour sub-segmentations to<br />

obtain cluster volumes and localised cluster VOI statistics for Ktrans. In each tumour a subset of clusters showed statistically<br />

significant post-treatment volume changes for at least one visit. Eight of 9 clusters with decreased volume had mean Ktrans > 0.127<br />

min-1. Reduced post-treatment volume in clusters with “high” Ktrans is consistent with reduced volume of actively-angiogenic<br />

tumour regions, as would be expected with a VEGF inhibitor. These effects would not be evident when using whole tumour VOI<br />

statistics.<br />

14:30 4814. Dynamic Contrast-Enhanced T 1 -Weighted Perfusion MRI Differentiates Tumor<br />

Recurrence from Radiation Necrosis: Relative Cerebral Blood Volume Measurements and<br />

FDG-PET Validation<br />

Vibeke Andrée Larsen 1 , Helle Juhl Simonsen 2 , Ian Law 3 , Henrik Pedersen 2 , Henrik BW<br />

Larsson 2 , Adam Espe Hansen 2<br />

1 Dept. of Radiology, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark; 2 Functional Imaging<br />

Unit, University of Copenhagen, Glostrup Hospital, Glostrup, Denmark; 3 PET and Cyclotron Unit,<br />

Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark<br />

The use of perfusion MRI for tumor characterization is complicated by the blood brain barrier deficiency. This preliminary study<br />

provides evidence that dynamic contrast enhanced T 1 weighted perfusion imaging can distinguish radiation-induced necrosis from<br />

tumor recurrence. We studied 9 patients after radiation treatment for gliomas and the results were validated with the FDG-PET gold<br />

standard. For 10 contrast enhancing lesions, 2 metabolically inactive lesions had relative cerebral blood volume (rCBV) of less than<br />

1.7, whereas 8 active lesions had rCBV greater than 2.0.<br />

15:00 4815. Relationship Between VEGF Receptor Expression and DCE-MRI Tracer Kinetic<br />

Parameters in Advanced Ovarian Cancer<br />

Caleb Roberts 1,2 , Claire L. Mitchell 3 , James P. O'Connor, 23 , Yvonne Watson 1,2 , Sue<br />

Cheung 1,2 , Alison Backen 4 , Caroline Dive 4 , Alan Jackson 1,2 , Gordon C. Jayson 3 , Geoff J.<br />

Parker 1,2<br />

1 Imaging Science and Biomedical Engineering, School of Cancer and Imaging Sciences, The University of<br />

Manchester, Manchester, United Kingdom; 2 The University of Manchester Biomedical Imaging Institute, The<br />

University of Manchester, Manchester, United Kingdom; 3 Cancer Research UK Dept Medical Oncology,<br />

Christie Hospital and University of Manchester, Manchester, United Kingdom; 4 Clinical and Experimental<br />

Pharmacology Group, Paterson Institute for Cancer Research, Manchester, United Kingdom<br />

The integration of imaging strategies such as dynamic contrast-enhanced MRI (DCE-MRI) in early phase drug development can help<br />

elucidate the underlying tumor physiology and assess drug efficacy. This study focuses on the relationships between serological<br />

expression of soluble VEGF receptors and DCE-MRI tracer kinetic parameters in a group of ovarian tumors. We observe striking<br />

relationships between the serological markers, K trans and v p that indicate that DCE-MRI is sensitive to specific aspects of the<br />

angiogenic process in these tumors.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!